AORT (41) DRTS (39) IRMD (59) SGP (43) ⌘ Pro Terminal →

PROCEPT BioRobotics Corporation (PRCT) — RQD Stock Rating Cockpit

$19.20 -5.42% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.98

PROCEPT BioRobotics Corporation (PRCT) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $1.16B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PRCT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PRCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $19.20 (-5.42% 1D, market cap $1.16B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, PRCT ranks #523 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PRCT compare to AORT and DRTS in the Health Care sector?

▼

Within the Health Care sector (Medical/Dental Instruments), PRCT carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 63.7%, and ROIC of -35.0%. By comparison, AORT (Artivion Inc.) holds a D- grade (41/100 RQD, P/E 117.0x, ROIC 4.5%, cap $1.14B) and DRTS (Alpha Tau Medical Ltd.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $1.22B). Among the 5-stock peer group, IRMD leads on earnings multiple (48.8x) while IRMD leads on capital efficiency (37.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PRCT?

▼

Per PRCT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001588978), PROCEPT BioRobotics Corporation generated $308.1M in revenue (+37.2% YoY), -$95.6K in net income, and -$58.3M in free cash flow against $508.1M in total assets and $51.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $18.98 (-1.17%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PRCT)Realized 20D OHLCV Swing Band: ±10.9%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY PRCT SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (35% of score)

Altman Z-Score 3.98 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Whale & Options Positioning+8/20 pts (20% of score)

20D Institutional Volume Accumulation (±10.9% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$19.57-6.6% Next Q

Q2 (-2Q)

Grade D$18.28+8.5% Next Q

Q3 (-1Q)

Grade D$19.83-3.2% Next Q

Current

Grade D-$19.20-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a PRCT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While PRCT currently carries a cautious 40/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.37) and Max Pain ($20.16) forces dealer call-delta covering toward $40.02.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PRCT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “PRCT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

57.230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.98>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE12% OF RANGE

L: $17$19.20H: $38

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: DRQD 20 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on PRCT

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (35)

-35.0% ROIC with 63.7% gross margin and -5.02% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 3.98 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

13/40 institutional & smart-money positioning score with 6/20 macro alignment.

Bull Case: Why Buyers Like PRCT

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PRCT)

✓Walkthrough of PRCT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PRCT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -22.67%📐 HORIZONTAL RANGE

2026-11-02O $20.20H $20.30L $19.20C $19.20VOL 704.6K

RES: $20.56SUP: $16.77SMA50: $19.37SMA200: $23.27

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PRCT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PRCT Butterfly Map → + Track PRCT →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +37.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PRCT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PRCT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PRCT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PRCT)

Health Care Rank #523 of 1016 ⚔️ AORT vs PRCT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PRCT vs. AORT, DRTS, IRMD, SGP)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, PROCEPT BioRobotics Corporation (PRCT) ranks #523 by composite RQD confidence (40/100, grade D-) and #341 by equity capitalization ($1.16B). Within this direct 5-issuer industry benchmark cohort, IRMD leads on earnings valuation at 48.8x trailing P/E, while IRMD leads on capital efficiency and profitability with 37.7% ROIC and 76.7% gross margin. IRMD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with PRCT at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PRCT ACTIVE PROCEPT BioRobotics Corporation	D-	40/100	—	63.7%	-35.0%	-5.42%	$1.16B	Benchmark Subject
AORT Artivion Inc.	D-	41/100	117.0x	64.4%	4.5%	-3.67%	$1.14B	/aort-vs-prct →
DRTS Alpha Tau Medical Ltd.	D-	39/100	—	—	-35.0%	-1.28%	$1.22B	/drts-vs-prct →
IRMD iRadimed Corporation	C-	59/100	48.8x	76.7%	37.7%	-10.57%	$1.10B	/irmd-vs-prct →
SGP SpyGlass Pharma Inc.	D-	43/100	—	—	-35.0%	-0.83%	$1.09B	/sgp-vs-prct →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001588978

In its most recent audited fiscal period (FY2025, filed 2025-12-31), PROCEPT BioRobotics Corporation (PRCT) reported GAAP revenue of $308.1M (+37.2% vs. FY2024 revenue of $224.5M , and +126.2% cumulative change since FY2023) , GAAP net income of -$95.6K, operating cash flow of -$49.0M, and free cash flow of -$58.3M (+43.7% YoY). On the balance sheet, PRCT closed FY2025 with $508.1M in total assets against $51.6M in total debt (Altman Z-Score: 3.98, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$308.1M	-$95.6K	-$49.0M	-$58.3M	$508.1M	$51.6M
FY2024 (FY)	2024-12-31	$224.5M	-$91.4K	-$99.2M	-$103.6M	$534.0M	$51.5M
FY2023 (FY)	2023-12-31	$136.2M	-$105.9K	-$108.0M	-$108.0M	—	—

3. PRCT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PRCT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does PRCT compare to AORT and DRTS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for PRCT?

Where is PRCT trading relative to its 50-day, 200-day, and 52-week technical levels?

PRCT last traded at $19.20 (-5.42% on volume of 856,501 shares), positioning the stock -0.88% below its 50-day simple moving average ($19.37) and -17.49% below its 200-day simple moving average ($23.27). Across its 52-week range of $16.67 to $38.11, PRCT sits at the 11.8% percentile with a 14-day RSI of 57.2 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.9% ($17.11 to $21.29).

PRCT Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PRCT stock right now?

PROCEPT BioRobotics Corporation (PRCT) currently earns a Roarable Rating of D- (Sell — SELL) with 40/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is PRCT's 12-month price target and RQD AI Jury consensus?

PRCT's 12-month base price target is $17.64 (range $13.76 to $40.02), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PRCT RQD Cockpit PRCT 12M Forecast PRCT Earnings & Move PRCT Dividends & DRIP PRCT Insiders & 13F PRCT Whale Options PRCT Profit Sankey PRCT News & Why

ROARABLE RATING BRIEF • RQD 40/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

PRCT — PROCEPT BioRobotics Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:30:26Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, PRCT scores 40 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 7 / 20. The rating cites ROIC of -35% and an FCF yield of -5.02%. For a prospective investor, this pillar indicates the business is not currently generating returns on invested capital or free cash flow to shareholders, so value depends on future cash generation that the source data does not project.
Whale 13F Flow: 8 / 20. The rating describes institutional accumulation and options positioning as a weak contributor. Holder-level detail is not available in source data, so the specific ownership changes behind this score cannot be verified here.
Insider Conviction: 5 / 20. Per the rating, SEC Form 4 and Congressional PTR cluster flow is the lowest-scoring pillar, implying insider activity does not offer strong conviction support.
Macro Regime Fit: 6 / 20. The rating reports a beta of 1.0 and sector sensitivity as a headwind, meaning the stock is expected to move in line with the broad market without a defensive offset.
Forensic Balance Sheet: 14 / 20. This is the strongest pillar, citing an Altman Z-Score of 3.98, a Piotroski F-Score of 4/9, and Debt/Equity of 0.14. Balance sheet solvency is comparatively sound, which partially offsets the weak cash flow and flow pillars.

Net effect for a prospective investor: the rating frames PRCT as a stock where liquidity and solvency are relatively protected, but operating losses, negative cash flow, and weak flow signals dominate the near-term case. Valuation tradeoffs center on the absence of positive earnings and cash flow metrics, which means the price of $20.30 cannot be tied to conventional earnings-based multiples from the source data.

Business

PROCEPT BioRobotics Corporation (PRCT) is a NASDAQ-listed company classified in the Health Care sector and the Medical/Dental Instruments industry. The source data does not describe its specific products, customers, or revenue model. The FY 2025 and FY 2024 figures show reported revenue, but the mechanism of revenue generation is not described in source data.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$308.1M	$-103.9M	$-0.1M	N/A	$-58.3M	$286.5M	$51.6M
FY 2024	$224.5M	$-96.6M	$-0.1M	N/A	$-103.6M	$333.7M	$51.5M
FY 2023	$136.2M	$-109.2M	$-0.1M	N/A	$-108.0M	N/A	N/A

Per the SEC financials, revenue rose from $136.2M (FY 2023) to $308.1M (FY 2025), while operating losses remained large in each period. Gross margin is 63.7% and operating margin is -33.7%; net margin is 0%. Per the Roarable RQD rating, ROIC is -35%, the Altman Z-Score is 3.98, and the Piotroski F-Score is 4/9. Cash declined from $333.7M to $286.5M across FY 2024 to FY 2025, and debt was $51.6M in FY 2025.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the items are:

RISK WATCH (RED): A Yahoo Finance report headlined around a possible lawsuit and board change, framed as a potential undervaluation catalyst.
CATALYST (GREEN): A Seeking Alpha report focused on growth of the company's Aquablation product line.
CATALYST (GREEN): A Yahoo Finance report on expected earnings beats.
MARKET WIRE (YELLOW): A MarketBeat report noting a "Hold" rating from Wall Street analysts.
MARKET WIRE (YELLOW): A Stock Titan report on a director receiving share and option rights.
MARKET WIRE (YELLOW): A Yahoo Finance report questioning whether the stock is fully priced on cash flow hopes.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Analyst View & Smart Money Ownership

Analyst consensus, price targets, and holder data are not available in source data. The only analyst-related reference is the MarketBeat headline describing a "Hold" rating, which is a news wire item and not a structured consensus figure. Form 4 insider, 13F institutional, and Congressional trade detail is not available in source data beyond the aggregate pillar scores in the Roarable RQD rating.

Open Questions

What are PRCT's specific products and revenue model, given the source data describes only its sector and industry?
What drove the increase in revenue from $136.2M to $308.1M while operating losses persisted, and what is the forward path to positive operating income?
What is the nature and scope of the lawsuit and board change referenced in the RED risk-watch headline?
What are the holdings, ownership changes, and insider transactions behind the 8/20 flow and 5/20 insider pillar scores?
Why are EPS and TTM earnings multiples unavailable, and what would normalize the valuation picture?

PRCT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for PROCEPT BioRobotics Corporation (PRCT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PRCT Debate Forum (3) ↓

🔴 RISK WATCH Yahoo Finance • 6h ago

PROCEPT BioRobotics (PRCT) Could Be 70% Undervalued On Lawsuit And Board Change

Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Seeking Alpha • 9h ago

PROCEPT BioRobotics: Compelling Bet On Aquablation's Growth

Seeking Alpha report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo Finance • 12h ago

PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 15h ago

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Stock Now Rated "Hold" by Wall Street Analysts

MarketBeat report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 18h ago

A director receives rights to 7,727 shares and options on 12,191 at PROCEPT BioRobotics (PRCT).

Stock Titan report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo Finance • 21h ago

PROCEPT BioRobotics (PRCT) Stock May Be Fully Priced On Cash Flow Hopes

Yahoo Finance report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE GlobeNewswire • 1d ago

Important Notice to Long-Term Shareholders of Aardvark

GlobeNewswire report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 1d ago

PROCEPT BioRobotics (NASDAQ:PRCT) Shares Up 4.3% - Still a Buy?

MarketBeat report covering PROCEPT BioRobotics Corporation (PRCT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PRCT Bull vs. Bear Conversation Board — What's Your Call at $19.20?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PRCT 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $17.86 (-12.0%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is PRCT (D- • RQD 40/100) a Buy at $20.30?

Welcome to the PRCT (PROCEPT BioRobotics Corporation) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $17.05 (-16.0%)

Spot @ $20.30

Pump the brakes on PRCT — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on PRCT, but look at what you are paying: current EV/EBITDA multiples with 63.7% gross margins. Unless PROCEPT BioRobotics Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $24.16 (+19.0%)

Spot @ $20.30

PRCT cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on PRCT, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $20.30 (52-wk range $16.67 - $38.11), any beat on forward guidance forces shorts and underweight funds to chase.